Trinity Biotech plc Sponsored ADR
Trinity Biotech develops, manufactures, and markets diagnostic systems, including reagents and instrumentation, for point-of-care and clinical laboratories.
Investor website: https://trinitybiotech.com/
About
Trinity Biotech develops, manufactures, and markets diagnostic systems, including reagents and instrumentation, for point-of-care and clinical laboratories. The company has recently entered the wearable biosensor industry. Their products detect a range of conditions, including infectious diseases, sexually transmitted diseases, autoimmune disorders, and haemoglobin disorders, while also monitoring diabetic markers. With a presence on the NASDAQ exchange, Trinity Biotech sells directly in the United States and through a network of international distributors and strategic partners in over 100 countries. The company is dedicated to improving patient care through innovative diagnostic solutions and has over 32 years of experience in delivering high-quality products for the diagnostics market, with FDA and ISO registered facilities in the US and Ireland.
Verified company data
- Shares outstanding
- 374,206,640
- Projects
- ["Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc. DUBLIN, Ireland, January 31, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring (“CGM”) assets of privately held Waveform Technologies, Inc. (“Waveform”) for $12.5 million in cash, 9 million American Depositary Shares (“ADSs”) of the Company and additional contingent consideration.","Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform DUBLIN, Ireland (October 25, 2024) – Trinity Biotech plc (Nasdaq: TRIB), a commercialstage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus’ groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test.","Trinity Biotech Announces Launch of FDA-cleared New Preeclampsia Testing Service"]
- Leadership
- Louise Tallon (CFO, Appointed as Chief Financial Officer in August 2024.), Des Fitzgerald (Interim CFO), David Ouston (Biosensor Marketing Director, Brings extensive commercial experience in glucose monitoring devices.), Jerry Lydon (Lead North America Commercial Operations)
Verified data last updated:
Recent filings
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-10-05_10-22-26.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-09-09_11-35-03.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-09-08_20-00-17.pdf
- Notice of Effectiveness · trib_2026-09-02_03-15-17.pdf
- Post-Effective amendments for registration statement · trib_2026-08-28_19-17-50.pdf
- Amendment Withdrawal Request · trib_2026-08-27_19-39-24.pdf
- [Amend] Registration statement for certain foreign private issuers · trib_2026-08-21_17-27-32.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-08-17_11-32-09.pdf